StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) company profile

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

About Atrium Therapeutics

Pharmaceutical Preparations, SIC 2834

Atrium Therapeutics, Inc. is listed on Nasdaq under the ticker RNA, in the SEC industry Pharmaceutical Preparations. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Atrium Therapeutics, Inc.
Headquarters
San Diego, CA
Address
3020 Callan Road 92121
Phone
(858) 401-7900
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31

Stock & identifiers

Ticker
RNA
Exchange
Nasdaq
IPO date
Feb 27, 2026
Shares outstanding
17M, Aug 3, 2026
Filer category
<br>Emerging growth company
SEC CIK
2093101
CUSIP
04965N104
ISIN
US04965N1046
FIGI
BBG01Z0T3959
Share class FIGI
BBG01Z0T3B63
EIN
39-4639499

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kathleen P. GallagherSee Remarks, Director119,729
Husam YounisChief Scientific Officer41,441
Steven George HughesChief Medical Officer51,638
Brendan R. WinslowChief Financial Officer36,859
Stephanie KenneySee Remarks33,085
Rocio Martin HoyosChief Strategy Officer38,340
W. Michael FlanaganDirector31,974
Sarah BoyceDirector138,668
Carsten BoessDirector11,005
Simona SkerjanecDirector5,902
Troy Edward WilsonDirector11,731

Corporate history

Events identified from SEC filings

See a number that looks wrong?